Eli Lilly (LLY) Cash from Financing Activities (2009 - 2026)

Eli Lilly (LLY) has reported Cash from Financing Activities for 18 consecutive years, with -$3.5 billion the latest figure, recorded in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$3.5 billion, down 351.45% year-over-year; the trailing twelve-month figure through Mar 2026 was -$7.1 billion (down 341.78% YoY), and the FY2025 annual result was -$2.2 billion, down 279.92% from the prior year.
• Cash from Financing Activities was -$3.5 billion for Q1 2026 at Eli Lilly, down from -$2.9 billion in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $3.5 billion in Q4 2023 and troughed at -$3.5 billion in Q1 2026.
• Average Cash from Financing Activities over 5 years is -$374.3 million, with a median of -$225.5 million recorded in 2024.
• The widest YoY moves for Cash from Financing Activities: up 543.3% in 2025, down 1176.63% in 2025.
• Over 5 years, Cash from Financing Activities stood at -$1.1 billion in 2022, then soared by 410.59% to $3.5 billion in 2023, then slumped by 106.36% to -$225.5 million in 2024, then sank by 1176.63% to -$2.9 billion in 2025, then slipped by 20.54% to -$3.5 billion in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$3.5 billion in Q1 2026, -$2.9 billion in Q4 2025, and $531.0 million in Q3 2025.